Duyuru • May 13
Fagron NV Approves Board Appointments Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation. Duyuru • May 12
Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026 Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026. Duyuru • Feb 27
Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million. Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V.
For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million.
Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026. Duyuru • Jan 07
Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio.
As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.
Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda.
Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026. Duyuru • Dec 21
Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd. Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum.
Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025. Duyuru • Nov 25
Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag. Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million.
Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. Duyuru • Nov 04
Fagron NV, Annual General Meeting, May 11, 2026 Fagron NV, Annual General Meeting, May 11, 2026. Duyuru • Oct 10
Fagron NV Reaffirms Earnings Guidance for the Fiscal Year 2025 Fagron NV reaffirmed earnings guidance for the fiscal year 2025. For the period, Company confirms revenue to be €930 million to €950 million and continue to expect a slight improvement in profitability year on year. Duyuru • Oct 06
Fagron Receives Brazilian Antitrust Clearance for Purifarma and Injeplast Acquisitions Fagron announced that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint. Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions. Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Duyuru • Sep 26
Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million. Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million on September 25, 2025. UCP generates around twenty five million dollars in annual revenue. The transaction will be fully financed through Fagron’s own resources and remains subject to customary clearance. Duyuru • Apr 11
Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC. Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin.
Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC on April 10, 2025. Duyuru • Feb 05
Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million. Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million on February 4, 2025. The acquisition will close on signing. Duyuru • Jan 08
Fagron NV, Annual General Meeting, May 12, 2025 Fagron NV, Annual General Meeting, May 12, 2025. Duyuru • Oct 11
Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH. Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH in the third quarter period ending September 30, 2024. Acquisition of EuroOTC raw materials will enhance our presence in Germany, creating synergies through increased scale and enhanced customer engagement. Duyuru • Oct 10
Fagron NV Reaffirms Earnings Guidance for the Full Year 2024 Fagron NV reaffirmed earnings guidance for the full year 2024. Maintain Full Year 2024 revenue outlook of €850 million to €870 million and improvement in profitability year-on-year. Reported Earnings • Aug 05
First half 2024 earnings released: EPS: €0.55 (vs €0.45 in 1H 2023) First half 2024 results: EPS: €0.55 (up from €0.45 in 1H 2023). Revenue: €429.3m (up 16% from 1H 2023). Net income: €40.4m (up 22% from 1H 2023). Profit margin: 9.4% (up from 8.9% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Declared Dividend • May 19
Dividend of €0.21 announced Shareholders will receive a dividend of €0.21. Ex-date: 21st May 2024 Payment date: 23rd May 2024 Dividend yield will be 1.1%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 39% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • May 15
Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024 The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 2023, and the remuneration policy. Ex-dividend date: 21 May 2024. Record date: 22 May 2024. Payment date: 23 May 2024. Duyuru • Apr 11
Fagron Provides Earnings Guidance for the Fiscal Year 2024 Fagron provided earnings guidance for the fiscal year 2024. For the year, the company expects high single-digit organic sales growth and improvement in profitability reaffirmed. Reported Earnings • Mar 19
Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022) Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €763.0m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 18
Full year 2023 earnings released: EPS: €0.97 (vs €0.95 in FY 2022) Full year 2023 results: EPS: €0.97 (up from €0.95 in FY 2022). Revenue: €767.2m (up 12% from FY 2022). Net income: €70.5m (up 1.3% from FY 2022). Profit margin: 9.2% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Duyuru • Feb 16
Fagron NV, Annual General Meeting, May 13, 2024 Fagron NV, Annual General Meeting, May 13, 2024. Duyuru • Oct 13
Fagron Nv Provides Earnings Guidance for 2023 Fagron NV provided earnings guidance for 2023. For full year revenue guidance, The company expects a EUR 750 million to EUR 770 million range. On profitability, the company reiterate guidance of year-on-year increase. Reported Earnings • Aug 06
First half 2023 earnings released: EPS: €0.45 (vs €0.48 in 1H 2022) First half 2023 results: EPS: €0.45 (down from €0.48 in 1H 2022). Revenue: €371.6m (up 13% from 1H 2022). Net income: €33.0m (down 6.1% from 1H 2022). Profit margin: 8.9% (down from 11% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 23
Full year 2022 earnings released: EPS: €0.95 (vs €0.84 in FY 2021) Full year 2022 results: EPS: €0.95 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €69.6m (up 14% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 10
Full year 2022 earnings released: EPS: €0.96 (vs €0.84 in FY 2021) Full year 2022 results: EPS: €0.96 (up from €0.84 in FY 2021). Revenue: €683.9m (up 19% from FY 2021). Net income: €70.1m (up 15% from FY 2021). Profit margin: 10% (in line with FY 2021). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Feb 09
Fagron Nv Proposes Dividend Fagron NV proposed Dividend of €0.25 per share. Board Change • Sep 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Els Vandecandelaere was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 05
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €26.8m from profit in 1H 2021). Profit margin: (down from 9.7% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 7.4%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Jun 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Neeraj Sharma was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 14
Full year 2021 earnings released: EPS: €0.84 (vs €0.83 in FY 2020) Full year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €573.8m (up 3.2% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 13%, compared to a 4.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. Buying Opportunity • Feb 15
Now 21% undervalued Over the last 90 days, the stock is up 9.6%. The fair value is estimated to be €20.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% per annum over the last 3 years. Earnings per share has grown by 8.0% per annum over the last 3 years. Reported Earnings • Feb 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €0.84 (up from €0.83 in FY 2020). Revenue: €577.9m (up 3.9% from FY 2020). Net income: €61.0m (up 2.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 08
First half 2021 earnings released: EPS €0.37 (vs €0.43 in 1H 2020) The company reported a poor first half result with weaker earnings and profit margins, although revenues were flat. First half 2021 results: Revenue: €276.6m (flat on 1H 2020). Net income: €26.9m (down 14% from 1H 2020). Profit margin: 9.7% (down from 11% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 04
New 90-day low: €18.69 The company is down 14% from its price of €21.72 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.91 per share. Is New 90 Day High Low • Sep 28
New 90-day high: €21.38 The company is up 15% from its price of €18.61 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.36 per share. 
